Blockade of Histone Deacetylase Inhibitor-Induced RelA/p65 Acetylation and NF-κB Activation Potentiates Apoptosis in Leukemia Cells through a Process Mediated by Oxidative Damage, XIAP Downregulation, and c-Jun N-Terminal Kinase 1 Activation

REFERENCES

• Adam, E., V. Quivy, F. Bex, A. Chariot, Y. Collette, C. Vanhulle, S. Schoonbroodt, V. Goffin, T. L. Nguyen, G. Gloire, G. Carrard, B. Friguet, Y. De Launoit, A. Burny, V. Bours, J. Piette, and C. Van Lint. 2003. Potentiation of tumor necrosis factor-induced NF-κB activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of IκBα. Mol. Cell. Biol. 23:6200–6209.
   PubMed Web of Science ®Google Scholar
• Amann, J. M., J. Nip, D. K. Strom, B. Lutterbach, H. Harada, N. Lenny, J. R. Downing, S. Meyers, and S. W. Hiebert. 2001. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell. Biol. 21:6470–6483.
   PubMed Web of Science ®Google Scholar
• Ashburner, B. P., S. D. Westerheide, and A. S. Baldwin, Jr. 2001. The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21:7065–7077.
   PubMed Web of Science ®Google Scholar
• Bennett, B. L., D. T. Sasaki, B. W. Murray, E. C. O'Leary, S. T. Sakata, W. Xu, J. C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, S. S. Bhagwat, A. M. Manning, and D. W. Anderson. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 98:13681–13686.
   PubMed Web of Science ®Google Scholar
• Bitterman, K. J., R. M. Anderson, H. Y. Cohen, M. Latorre-Esteves, and D. A. Sinclair. 2002. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 277:45099–45107.
   PubMed Web of Science ®Google Scholar
• Briggs, S. D., T. Xiao, Z. W. Sun, J. A. Caldwell, J. Shabanowitz, D. F. Hunt, C. D. Allis, and B. D. Strahl. 2002. Gene silencing: trans-histone regulatory pathway in chromatin. Nature 418:498.
   PubMed Web of Science ®Google Scholar
• Brown, P. H., T. K. Chen, and M. J. Birrer. 1994. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 9:791–799.
   PubMed Web of Science ®Google Scholar
• Byun, M. S., K. I. Jeon, J. W. Choi, J. Y. Shim, and D. M. Jue. 2002. Dual effect of oxidative stress on NF-kappakB activation in HeLa cells. Exp. Mol. Med. 34:332–339.
   PubMed Web of Science ®Google Scholar
• Chen, C., L. C. Edelstein, and C. Gelinas. 2000. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL. Mol. Cell. Biol. 20:2687–2695.
   PubMed Web of Science ®Google Scholar
• Chen, F., V. Castranova, Z. Li, M. Karin, and X. Shi. 2003. Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic. Cancer Res. 63:7689–7693.
   PubMedGoogle Scholar
• Chen, L. F., and W. C. Greene. 2004. Shaping the nuclear action of NF-kappaB. Nat. Rev. Mol. Cell Biol. 5:392–401.
   PubMed Web of Science ®Google Scholar
• Chen, L. F., W. Fischle, E. Verdin, and W. C. Greene. 2001. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293:1653–1657.
   PubMed Web of Science ®Google Scholar
• Chen, L. F., Y. Mu, and W. C. Greene. 2002. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 21:6539–6548.
   PubMed Web of Science ®Google Scholar
• Chen, L. F., and W. C. Greene. 2003. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J. Mol. Med. 81:549–557.
   PubMed Web of Science ®Google Scholar
• Chen, W. Y., and T. M. Townes. 2000. Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation. Proc. Natl. Acad. Sci. USA 97:377–382.
   PubMed Web of Science ®Google Scholar
• Dai, S., T. Hirayama, S. Abbas, and Y. Abu-Amer. 2004. The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J. Biol. Chem. 279:37219–37222.
   PubMedGoogle Scholar
• Dai, Y., C. Yu, V. Singh, L. Tang, Z. Wang, R. McInistry, P. Dent, and S. Grant. 2001. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 61:5106–5115.
   PubMed Web of Science ®Google Scholar
• Dai, Y., M. Rahmani, and S. Grant. 2003. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 22:7108–7122.
   PubMed Web of Science ®Google Scholar
• Dai, Y., P. Dent, and S. Grant. 2003. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL. Mol. Pharmacol. 64:1402–1409.
   PubMed Web of Science ®Google Scholar
• Datta, R, E. Oki, K. Endo, V. Biedermann, J. Ren, and D. Kufe. 2000. XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. J. Biol. Chem. 275:31733–31738.
   PubMedGoogle Scholar
• Dhar, S. K., B. C. Lynn, C. Daosukho, and D. K. St. Clair. 2004. Identification of nucleophosmin as an NF-kappaB co-activator for the induction of the human SOD2 gene. J. Biol. Chem. 279:28209–28219.
   PubMed Web of Science ®Google Scholar
• Filomeni, G., K. Aquilano, G. Rotilio, and M. R. Ciriolo. 2003. Reactive oxygen species-dependent c-Jun NH2-terminal kinase/c-Jun signaling cascade mediates neuroblastoma cell death induced by diallyl disulfide. Cancer Res. 63:5940–5949.
   PubMed Web of Science ®Google Scholar
• Finnin, M. S., J. R. Donigian, A. Cohen, V. M. Richon, R. A. Rifkind, P. A. Marks, R. Breslow, and N. P. Pavletich. 1999. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188–193.
   PubMed Web of Science ®Google Scholar
• Fuino, L., P. Bali, S. Wittmann, S. Donapaty, F. Guo, H. Yamaguchi, H. G. Wang, P. Atadja, and K. Bhalla. 2003. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2:971–984.
   PubMed Web of Science ®Google Scholar
• Garcia-Bermejo, L., N. E. Vilaboa, C. Perez, A. Galan, E. De Blas, and P. Aller. 1997. Modulation of heat-shock protein 70 (HSP70) gene expression by sodium butyrate in U-937 promonocytic cells: relationships with differentiation and apoptosis. Exp. Cell Res. 236:268–274.
   PubMedGoogle Scholar
• Guo, Z., G. H. Boekhoudt, and J. M. Boss. 2003. Role of the intronic enhancer in tumor necrosis factor-mediated induction of manganous superoxide dismutase. J. Biol. Chem. 278:23570–23578.
   PubMedGoogle Scholar
• Hildeman, D. A., T. Mitchell, B. Aronow, S. Wojciechowski, J. Kappler, and P. Marrack. 2003. Control of Bcl-2 expression by reactive oxygen species. Proc. Natl. Acad. Sci. USA 100:15035–15040.
   PubMed Web of Science ®Google Scholar
• Huang, H. L., L. W. Fang, S. P. Lu, C. K. Chou, T. Y. Luh, and M. Z. Lai. 2003. DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation. Oncogene 22:8168–8177.
   PubMed Web of Science ®Google Scholar
• Huang, P., L. Feng, E. A. Oldham, M. J. Keating, and W. Plunkett. 2000. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407:390–395.
   PubMed Web of Science ®Google Scholar
• Huang, T. T., N. Kudo, M. Yoshida, and S. Miyamoto. 2000. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc. Natl. Acad. Sci. USA 97:1014–1019.
   PubMed Web of Science ®Google Scholar
• Huang, T. T., S. M. Wuerzberger-Davis, Z. H. Wu, and S. Miyamoto. 2003. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 115:565–576.
   PubMed Web of Science ®Google Scholar
• Johnstone, R. W. 2002. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1:287–299.
   PubMed Web of Science ®Google Scholar
• Kiernan, R., V. Bres, R. W. Ng, M. P. Coudart, S. El Messaoudi, C. Sardet, D. Y. Jin, S. Emiliani, and M. Benkirane. 2003. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278:2758–2766.
   PubMed Web of Science ®Google Scholar
• Kiningham, K. K., C. Daosukho, and D. K. St. Clair. 2004. IkappaB-alpha identified as labile repressor of manganese superoxide dismutase (MnSOD) expression. Biochem J. 384:543–549.
   PubMedGoogle Scholar
• Lappas, M., K. Yee, M. Permezel, and G. E. Rice. 2005. Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-kappa B and I kappa B kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology 146:1491–1497.
   PubMed Web of Science ®Google Scholar
• Leach, J. K., G. V. Tuyle, P. S. Lin, R. Schmidt-Ullrich, and R. B. Mikkelsen. 2001. Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen. Cancer Res. 61:3894–3901.
   PubMed Web of Science ®Google Scholar
• Li, J., M. J. Staver, M. L., Curtin, J. H. Holms, R. R. Frey, R. Edalji, R. Smith, M. R. Michaelides, S. K. Davidsen, and K. B. Glaser. 2004. Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sci. 74:2693–2705.
   PubMedGoogle Scholar
• Lin, Y. Z., S. Y. Yao, R. A. Veach, T. R. Torgerson, and J. Hawiger. 1995. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. 270:14255–14258.
   PubMed Web of Science ®Google Scholar
• Maggio, S. C., R. R. Rosato, L. B. Kramer, Y. Dai, M. Rahmani, D. S. Paik, A. C. Czarnik, S. G. Payne, S. Spiegel, and S. Grant. 2004. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 64:2590–2600.
   PubMed Web of Science ®Google Scholar
• Marks, P., R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller, and W. K. Kelly. 2001. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1:194–202.
   PubMed Web of Science ®Google Scholar
• Mayo, M. W., C. E. Denlinger, R. M. Broad, F. Yeung, E. T. Reilly, Y. Shi, and D. R. Jones. 2003. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J. Biol. Chem. 278:18980–18989.
   PubMed Web of Science ®Google Scholar
• Palombella, V. J., E. M. Conner, J. W. Fuseler, A. Destree, J. M. Davis, F. S. Laroux, R. E. Wolf, J. Huang, S. Brand, P. J. Elliott, D. Lazarus, T. McCormack, L. Parent, R. Stein, J. Adams, and M. B. Grisham. 1998. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA 95:15671–15676.
   PubMed Web of Science ®Google Scholar
• Pei, X. Y., Y. Dai, and S. Grant. 2004. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor Bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 10:3839–3852.
   PubMed Web of Science ®Google Scholar
• Pierce, J. W., R. Schoenleber, G. Jesmok, J. Best, S. A. Moore, T. Collins, and M. E. Gerritsen. 1997. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272:21096–21103.
   PubMed Web of Science ®Google Scholar
• Reuther-Madrid, J. Y., D. Kashatus, S. Chen, X. Li, J. Westwick, R. J. Davis, H. S. Earp, C. Y. Wang, and A. S. Baldwin, Jr. 2002. The p65/RelA subunit of NF-κB suppresses the sustained, antiapoptotic activity of Jun kinase induced by tumor necrosis factor. Mol. Cell. Biol. 22:8175–8183.
   PubMed Web of Science ®Google Scholar
• Richon, V. M., S. Emiliani, E. Verdin, Y. Webb, R. Breslow, R. A. Rifkind, and P. A. Marks. 1998. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 95:3003–3007.
   PubMed Web of Science ®Google Scholar
• Rosato, R. R., J. A. Almenara, and S. Grant. 2003. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 Cancer Res. 63:3637–3645.
   Google Scholar
• Ruefli, A. A., M. J. Ausserlechner, D. Bernhard, V. R. Sutton, K. M. Tainton, R. Kofler, M. J. Smyth, and R. W. Johnstone. 2001. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 98:10833–10838.
   PubMed Web of Science ®Google Scholar
• Ryan, K. M., M. K. Ernst, N. R. Rice, and K. H. Vousden. 2000. Role of NF-kappaB in p53-mediated programmed cell death. Nature 404:892–897.
   PubMed Web of Science ®Google Scholar
• Saito, A., T. Yamashita, Y. Mariko, Y. Nosaka, K. Tsuchiya, T. Ando, T. Suzuki, T. Tsuruo, and O. Nakanishi. 1999. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 96:4592–4597.
   PubMed Web of Science ®Google Scholar
• Schreck, R., P. Rieber, and P. A. Baeuerle. 1991. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 10:2247–2258.
   PubMed Web of Science ®Google Scholar
• Schubeler, D., D. M. MacAlpine, D. Scalzo, C. Wirbelauer, C. Kooperberg, F. van Leeuwen, D. E. Gottschling, L. P. O'Neill, B. M. Turner, J. Delrow, S. P. Bell, and M. Groudine. 2004. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev. 18:1263–1271.
   PubMed Web of Science ®Google Scholar
• Srinivasula, S. M., R. Hegde, A. Saleh, P. Datta, E. Shiozaki, J. Chai, R. A. Lee, P. D. Robbins, T. Fernandes-Alnemri, Y. Shi, and E. S. Alnemri. 2001. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410:112–116.
   PubMed Web of Science ®Google Scholar
• Stehlik, C., R. de Martin, I. Kumabashiri, J. A. Schmid, B. R. Binder, and J. Lipp. 1998. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J. Exp. Med. 188:211–216.
   PubMed Web of Science ®Google Scholar
• Tang, G., Y. Minemoto, B. Dibling, N. H. Purcell, Z. Li, M. Karin, and A. Lin. 2001. Inhibition of JNK activation through NF-kappaB target genes. Nature 414:313–317.
   PubMed Web of Science ®Google Scholar
• Tournier, C., P. Hess, D. D. Yang, J. Xu, T. K. Turner, A. Nimnual, D. Bar-Sagi, S. N. Jones, R. A. Flavell, and R. J. Davis. 2000. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288:870–874.
   PubMed Web of Science ®Google Scholar
• Ungerstedt, J. S., Y. Sowa, W. S. Xu, Y. Shao, M. Dokmanovic, G. Perez, L. Ngo, A. Holmgren, X. Jiang, and P. A. Marks. 2005. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 102:673–678.
   PubMed Web of Science ®Google Scholar
• Verheij, M., R. Bose, X. H. Lin, B. Yao, W. D. Jarvis, S. Grant, M. J. Birrer, E. Szabo, L. I. Zon, J. M. Kyriakis, A. Haimovitz-Friedman, Z. Fuks, and R. N. Kolesnick. 1996. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380:75–79.
   PubMed Web of Science ®Google Scholar
• Wen, Y. D., V. Perissi, L. M. Staszewski, W. M. Yang, A. Krones, C. K. Glass, M. G. Rosenfeld, and E. Seto. 2000. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci. USA 97:7202–7207.
   PubMed Web of Science ®Google Scholar
• Yeung, F., J. E. Hoberg, C. S. Ramsey, M. D. Keller, D. R. Jones, R. A. Frye, and M. W. Mayo. 2004. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23:2369–2380.
   PubMed Web of Science ®Google Scholar
• Yin, L., G. Laevsky, and C. Giardina. 2001. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J. Biol. Chem. 276:44641–44646.
   PubMed Web of Science ®Google Scholar
• Yu, C., M. Rahmani, D. Conrad, M. Subler, P. Dent, and S. Grant. 2003. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 102:3765–3774.
   PubMed Web of Science ®Google Scholar
• Zelko, I. N., T. J. Mariani, and R. J. Folz. 2002. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic. Biol. Med. 33:337–349.
   PubMed Web of Science ®Google Scholar
• Zhang, J., M. Kalkum, B. T. Chait, and R. G. Roeder. 2002. The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol. Cell 9:611–623.
   PubMed Web of Science ®Google Scholar